Krystal Biotech
$38.509876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$38.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$2.00 (-4.94%) Today
$0.00 (0.00%) As of 6:00 PM EDT after-hours
Why Robinhood?
You can buy or sell KRYS and other stocks, options, ETFs, and crypto commission-free!
About KRYS
Krystal Biotech, Inc. Common Stock, also called Krystal Biotech, is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. Read More It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Employees
51
Headquarters
Pittsburgh, Pennsylvania
Founded
2016
Market Cap
654.40M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
155.44K
High Today
$40.26
Low Today
$38.02
Open Price
$39.05
Volume
84.72K
52 Week High
$66.85
52 Week Low
$22.02
Collections
Analyst Ratings
86%
of 7 ratings
Buy
86%
Hold
14%
Sell
0%
KRYS Earnings
-$0.37
-$0.25
-$0.12
$0.00
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected May 4, Pre-Market